Cara Therapeutics, Inc. (NASDAQ:CARA) had its target price upped by CIBC from $28.00 to $29.00 in a report issued on Monday, May 15th, StockTargetPrices.com reports.

Other equities research analysts have also issued research reports about the stock. Vetr raised shares of Cara Therapeutics from a sell rating to a strong-buy rating and set a $16.96 price objective on the stock in a research note on Tuesday, January 17th. HC Wainwright boosted their price objective on shares of Cara Therapeutics from $22.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 28th. Canaccord Genuity reissued a buy rating and set a $25.00 price objective on shares of Cara Therapeutics in a research note on Friday, March 10th. Zacks Investment Research lowered shares of Cara Therapeutics from a hold rating to a sell rating in a research note on Tuesday, March 14th. Finally, Piper Jaffray Companies reissued a positive rating and set a $23.00 price objective on shares of Cara Therapeutics in a research note on Tuesday, March 28th. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Cara Therapeutics has an average rating of Buy and a consensus target price of $26.17.

Cara Therapeutics (NASDAQ CARA) remained flat at $17.12 during mid-day trading on Monday. 6,862,360 shares of the stock traded hands. Cara Therapeutics has a 1-year low of $4.35 and a 1-year high of $20.90. The company has a 50-day moving average of $16.60 and a 200 day moving average of $14.71. The stock’s market capitalization is $556.52 million.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by $0.08. The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $0.11 million. The company’s revenue for the quarter was up 12900.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.39) EPS. Equities analysts predict that Cara Therapeutics will post ($2.37) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/06/16/cara-therapeutics-inc-cara-pt-raised-to-29-00-updated-updated-updated.html.

In related news, major shareholder Ventures Vi Lp Rho bought 500,000 shares of the firm’s stock in a transaction on Friday, March 31st. The shares were bought at an average price of $18.19 per share, with a total value of $9,095,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Cara Therapeutics by 127.2% in the third quarter. Wells Fargo & Company MN now owns 12,007 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 6,722 shares during the period. Private Advisor Group LLC purchased a new stake in Cara Therapeutics during the fourth quarter valued at $117,000. Quantbot Technologies LP purchased a new stake in Cara Therapeutics during the first quarter valued at $124,000. Flinton Capital Management LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter valued at $139,000. Finally, UBS Group AG increased its stake in shares of Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares in the last quarter. 54.84% of the stock is owned by hedge funds and other institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Stock Target Prices

Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.